These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 34985726)
21. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer. Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700 [TBL] [Abstract][Full Text] [Related]
22. BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy. Takada M; Nagai S; Haruta M; Sugino RP; Tozuka K; Takei H; Ohkubo F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Sato Y; Ogawa S; Kaneko Y Genes Chromosomes Cancer; 2017 May; 56(5):405-420. PubMed ID: 28124401 [TBL] [Abstract][Full Text] [Related]
23. Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer. Wang Y; Ung MH; Cantor S; Cheng C Sci Rep; 2017 Nov; 7(1):15742. PubMed ID: 29146938 [TBL] [Abstract][Full Text] [Related]
24. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285 [TBL] [Abstract][Full Text] [Related]
25. BRCAness Combined With a Family History of Cancer Is Associated With a Poor Prognosis for Breast Cancer Patients With a High Risk of BRCA Mutations. Mori H; Kubo M; Kai M; Velasquez VV; Kurata K; Yamada M; Okido M; Kuroki S; Oda Y; Nakamura M Clin Breast Cancer; 2018 Oct; 18(5):e1217-e1227. PubMed ID: 29941390 [TBL] [Abstract][Full Text] [Related]
26. Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment. Jwa E; Shin KH; Kim JY; Park YH; Jung SY; Lee ES; Park IH; Lee KS; Ro J; Kim YJ; Kim TH Cancer Res Treat; 2016 Oct; 48(4):1363-1372. PubMed ID: 26910473 [TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer. Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542 [TBL] [Abstract][Full Text] [Related]
28. Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer. Branham MT; Campoy E; Laurito S; Branham R; Urrutia G; Orozco J; Gago F; Urrutia R; Roqué M Breast Cancer Res Treat; 2016 Jan; 155(1):13-23. PubMed ID: 26610810 [TBL] [Abstract][Full Text] [Related]
29. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy. Darb-Esfahani S; Loibl S; Müller BM; Roller M; Denkert C; Komor M; Schlüns K; Blohmer JU; Budczies J; Gerber B; Noske A; du Bois A; Weichert W; Jackisch C; Dietel M; Richter K; Kaufmann M; von Minckwitz G Breast Cancer Res; 2009; 11(5):R69. PubMed ID: 19758440 [TBL] [Abstract][Full Text] [Related]
30. Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer. Murria Estal R; Palanca Suela S; de Juan Jiménez I; Alenda Gonzalez C; Egoavil Rojas C; García-Casado Z; López Guerrero JA; Juan Fita MJ; Sánchez Heras AB; Segura Huerta Á; Santaballa Bertrán A; Chirivella González I; Llop García M; Pérez Simó G; Barragán González E; Bolufer Gilabert P Fam Cancer; 2016 Apr; 15(2):193-200. PubMed ID: 26723934 [TBL] [Abstract][Full Text] [Related]
31. CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy. Tokunaga E; Fujita A; Takizawa K; Baba K; Akiyoshi S; Nakamura Y; Ijichi H; Masuda T; Koga C; Tajiri W; Ohno S; Taguchi K; Ishida M Breast Cancer; 2019 Jan; 26(1):47-57. PubMed ID: 29971631 [TBL] [Abstract][Full Text] [Related]
32. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer. Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556 [TBL] [Abstract][Full Text] [Related]
33. Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study. Kim SH; Jung KH; Kim TY; Im SA; Choi IS; Chae YS; Baek SK; Kang SY; Park S; Park IH; Lee KS; Choi YJ; Lee S; Sohn JH; Park YH; Im YH; Ahn JH; Kim SB; Kim JH Cancer Res Treat; 2016 Oct; 48(4):1373-1381. PubMed ID: 27034147 [TBL] [Abstract][Full Text] [Related]
34. Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy. Chou HH; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Yu MC; Lo YF; Dabora MA; Chang HK; Lin YC; Ueng SH; Chen SC Biomed J; 2019 Feb; 42(1):66-74. PubMed ID: 30987708 [TBL] [Abstract][Full Text] [Related]
35. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype. Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067 [TBL] [Abstract][Full Text] [Related]
36. Complete pathologic response rate to neoadjuvant chemotherapy increases with increasing HER2/CEP17 ratio in HER2 overexpressing breast cancer: analysis of the National Cancer Database (NCDB). Greenwell K; Hussain L; Lee D; Bramlage M; Bills G; Mehta A; Jackson A; Wexelman B Breast Cancer Res Treat; 2020 Jun; 181(2):249-254. PubMed ID: 32277375 [TBL] [Abstract][Full Text] [Related]
37. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer. Matsubara N; Mukai H; Fujii S; Wada N Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081 [TBL] [Abstract][Full Text] [Related]
38. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study. Chen Y; Chen K; Xiao X; Nie Y; Qu S; Gong C; Su F; Song E BMC Cancer; 2016 May; 16():320. PubMed ID: 27198767 [TBL] [Abstract][Full Text] [Related]
39. Loss of BRCA1 protein expression as indicator of the BRCAness phenotype is associated with favorable overall survival after complete resection of sporadic ovarian cancer. Radosa MP; Häfner N; Camara O; Diebolder H; Mothes A; Winzer H; Jansen L; Dürst M; Runnebaum IB Int J Gynecol Cancer; 2011 Nov; 21(8):1399-406. PubMed ID: 21897273 [TBL] [Abstract][Full Text] [Related]
40. Factors affecting locoregional recurrence in breast cancer patients undergoing surgery following neoadjuvant treatment. Chou HH; Chung WS; Ding RY; Kuo WL; Yu CC; Tsai HP; Shen SC; Chu CH; Lo YF; Chen SC BMC Surg; 2021 Mar; 21(1):160. PubMed ID: 33757489 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]